These findings not only spotlight novel therapeutic targets, particularly SEPTIN3, DPP10 and ACADSB, but also underscore the necessity for further mechanistic studies to fully understand their roles in the pathogenesis and treatment of specific lung cancer subtypes. Here, ACADSB is linked to lung carcinoma.